A study to assess the effectiveness of cetrizine as an additional therapeutic agent to standard therapy,in comparison to placebo in limited patchy alopecia areata

Efficacy of cetrizine in limited patchy alopecia areata – A randomised placebo-controlled single centre study.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/03/031832

Enrollment

Registered

2021-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: Cetrizine: oral route single tablet 10mg HS for 24 weeks Control Intervention1: Placebo: oral route single tablet Hs for 24 weeks

Eligibility

Inclusion criteria

Inclusion criteria: All patients diagnosed by consensus by investigators having limited patchy alopecia areata.

Exclusion criteria

Exclusion criteria: Patients on steroids or immunosuppressants for any other condition. Pregnancy & lactation Children less than 18 years

Design outcomes

Primary

Measure	Time frame
Fall in SALT scoreTimepoint: Baseline, 4 wks, 8 wks, 12 wks, 24 weeks	—

Secondary

Measure	Time frame
Fall in DLQITimepoint: 24 weeks;Frequency of adverse effectsTimepoint: 24 weeks;time to recurrenceTimepoint: 48 weeks	—

Countries

India

Contacts

Public ContactDrSarithaM

Indira Gandhi Medical College and Research institute

saritha_mohanan@yahoo.co.in09443397873

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026